U.K. CELL AND GENE THERAPY RESEARCH CHALLENGES MARKET ANALYSIS

U.K. Cell and Gene Therapy Research Challenges Market, by Therapy Type (Cell Therapy (Stem Cells, T Cells, Dendritic Cells, and NK Cells) and Gene Therapy (Germline Gene Therapy and Somatic Gene Therapy)), and by Indication (Dermatology, Musculoskeletal, Oncology, Immunology, Cardiology & Neurology, and Others) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Jan 2022
Code : CMI4889
Pages :140
Formats :
Excel and PDF
Industry : Biotechnology

Market Challenges And Opportunities

U.K. Cell and Gene Therapy Research Challenges Market - Restraint

Unfavourable reimbursement policies and manufacturing issues limiting the availability of products at treatment centres are expected to hinder growth of the U.K. cell and gene therapy research challenges market over the forecast period. However, cell and gene therapy has witnessed multiple setbacks from regulatory authorities in charge of reimbursement policy, which is expected to inhibit growth of the market.

For instance, in August 2018, the National Institute for Health and Care Excellence (NICE), U.K. concluded that Yescarta is a very expensive therapy and hence cannot be considered as a cost-effective use of National Health System (NHS) resources.

Growth Drivers:

Increasing approval and launch of novel gene therapies for treatment of various rare diseases
Robust pipeline of products
Rising research and development activities for the development of novel technology